J. Keen

发表

Skeletal Complications of Malignancy Supplement to Cancer The Biology of Breast Carcinoma

N. Davidson, J. Keen, 2003 .

N. Davidson, J. Keen, Nancy E Davidson, 2003, Cancer.

Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells

B. Park, K. Bachman, H. Konishi, 2006, Breast Cancer Research and Treatment.

Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals.

Sonja W. Scholz, John Hardy, Mar Matarin, 2007, Human molecular genetics.

Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes.

D. Cameron, J. Keen, W. Miller, 2000, European journal of cancer.

Expression of transforming growth factor beta mRNA isoforms in human breast cancer.

J. Bartlett, J. Keen, W. Miller, 1994, British Journal of Cancer.

Protein Phosphatase 2A Regulates Estrogen Receptor α (ER) Expression through Modulation of ER mRNA Stability*

B. Park, N. Davidson, J. Keen, 2005, Journal of Biological Chemistry.

Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence

J. Keen, P. Melera, O. Obajimi, 2009, The Prostate.

P-glycoprotein and resistance to tamoxifen

J. Keen, W. Miller, C. Bellamy, 1994, The Lancet.

The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer

D. Cameron, U. Chetty, J. Dixon, 1997, Breast Cancer Research and Treatment.

Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells.

L. Marton, N. Davidson, J. Keen, 2004, Molecular cancer research : MCR.

Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells*

S. Sukumar, B. Park, L. Marton, 2006, Journal of Biological Chemistry.

A step towards a new targeted nanotherapy for pancreatic cancer

J. Keen, 2008, Cancer biology & therapy.

The ASTRO Research Portfolio: Where Do We Go From Here?

K. Brock, E. Moros, Anurag K. Singh, 2019, International journal of radiation oncology, biology, physics.

Breast Cancer Cell Line Development and Authentication

J. Keen, 2011 .

Histone deacetylation inhibits IL4 gene expression in T cells.

J. Schroeder, V. Casolaro, S. Georas, 2002, The Journal of allergy and clinical immunology.

Characterization of a novel PMA‐inducible pathway of interleukin‐13 gene expression in T cells

V. Casolaro, S. Georas, J. Keen, 2006, Immunology.

Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.

J. Bartlett, J. Keen, W. Miller, 1996, British Journal of Cancer.

Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR

J. Keen, O. Obajimi, P. Pryzbylkowski, 2008, Breast Cancer Research and Treatment.

A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine

Dipali Sharma, N. Davidson, J. Keen, 2003, Breast Cancer Research and Treatment.

The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines

J. Keen, J. Crismale, L. Licata, 2010, Breast Cancer Research and Treatment.

Yin-Yang 1 Activates Interleukin-4 Gene Expression in T Cells*

Wen‐Ming Yang, V. Casolaro, S. Georas, 2001, The Journal of Biological Chemistry.

pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs

M. Gorospe, G. Gonye, C. L. Costantino, 2010, PloS one.

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

M. Gorospe, C. L. Costantino, C. Yeo, 2009, Cancer research.

The 'RNA-binding ome': future implications for chemotherapeutic efficacy.

M. Gorospe, C. Yeo, J. Keen, 2009, Future oncology.

Protein Phosphatase 2A (PP2A) regulates Estrogen Receptor Alpha (ER) expression through modulation of ER mRNA stability.

B. Park, N. Davidson, J. Keen, 2005 .

Preferential activation of nuclear factor of activated T cells c correlates with mouse strain susceptibility to allergic responses and interleukin-4 gene expression.

S. Georas, J. Keen, M. Wills-Karp, 2001, American journal of respiratory cell and molecular biology.

Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells

C. L. Costantino, C. Yeo, J. Keen, 2008, Cancer biology & therapy.

Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology.

Adam P Dicker, A. Dicker, K. Mouw, 2018, JCO clinical cancer informatics.

Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.

J. Keen, L. Licata, Christine L. Hostetter, 2009, Cancer letters.

Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells

J. Herman, N. Davidson, J. Keen, 2004, Cancer biology & therapy.

Abstract 4063: Estrogen receptor alpha functions as an RNA binding protein to regulate GATA3 protein levels: a novel role for ER

J. Keen, G. Chamoun, Christine L. Hostetter, 2010 .